Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström Syndromes

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence